Subscribe
shutterstock_1653845269_taljat_david
Taljat David / Shutterstock.com
23 June 2022Big Pharma

Fed Circuit reverses Novartis’ drug patent win

The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Federal Circuit denies Novartis’ bid to halt generics
29 September 2022   Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.
Americas
Swiss pharma company reveals SCOTUS appeal plans
22 September 2022   Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.
Big Pharma
Swiss watchdog investigates Novartis over patent use
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Federal Circuit denies Novartis’ bid to halt generics
29 September 2022   Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.
Americas
Swiss pharma company reveals SCOTUS appeal plans
22 September 2022   Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.
Big Pharma
Swiss watchdog investigates Novartis over patent use
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

More on this story

Big Pharma
Federal Circuit denies Novartis’ bid to halt generics
29 September 2022   Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.
Americas
Swiss pharma company reveals SCOTUS appeal plans
22 September 2022   Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.
Big Pharma
Swiss watchdog investigates Novartis over patent use
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims